SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
Category: News
Phase 3 results highlight metabolic benefits alongside weight loss
Late‑breaking EULAR results highlight sustained responses through week 52
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
Early clinical activity supports expansion into broader IgA‑mediated conditions
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
New collaboration aims to break barriers in brain‑targeted drug discovery
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
